ONC Share Price Performance
Recent ONC News & Updates
No updates
Oncolytics Biotech Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.33
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Oncolytics Biotech Inc. Competitors
About ONC
- Founded
- 1998
- Employees
- 28
- CEO
- WebsiteView website
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Canadian Market Performance
- 7 Days: 0.2%
- 3 Months: 11.0%
- 1 Year: 18.3%
- Year to Date: 10.3%
The market has been flat in the last week, however the Industrials sector is down 3.0%. Meanwhile, the market is actually up 18% over the past year. Earnings are forecast to grow by 12% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading